INTRODUCTION

Basiliximab (brand name Simulect) is a chimeric mouse-human monoclonal antibody (mAb) targeting interleukin 2 receptor subunit alpha (IL2RA, CD25). Basiliximab is used as an immunosuppressant agent to prevent rejection in organ transplantation, especially in kidney transplants.

This plasmid is designed for expressing Basiliximab in mammalian cells such as HEK293, or Chinese hamster ovary (CHO) cell line. We provide multiple options for Basiliximab expression, either single-vector-based expression or two-vector-based expression.

PRODUCT INFORMATION

Item No.: PPBD-30
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Basiliximab
Brand Names: Simulect
Classification: Monoclonal antibody (mAb)
Target: Interleukin 2 receptor subunit alpha (IL2RA, CD25, IDDM10, IL2R, IMD41, TCGFR, p55)
Action Type: Inhibitor, immunosuppressive therapy
Amino Acid Sequence: Identical to DB00074

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Bluestone JA, Liu W, Yabu JM, Laszik ZG, Putnam A, Belingheri M, Gross DM, Townsend RM, Vincenti F. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008 Oct;8(10):2086-96.

Contact Us